novartis_rm_logo_pos_rgb.png
Haematology masterlass_logo_FULL_v.08.pn
Sign up to be an approver

This promotional meeting is organised and funded by Novartis Pharmaceuticals UK Limited.

UK | February 2021 | 105991

Adverse events should be reported. Reporting forms and information can be found at  www.mhra.gov.UK/yellowcard (UK).

Adverse events should also be reported to Novartis via  uk.patientsafety@novartis.com or online through the pharmacovigilance intake (PVI) tool at  www.report.novartis.com

If you have a question about a product, please contact Medical Information on 01276 698370 or by email at  medinfo.uk@novartis.com

To learn about your data privacy rights and the use of your personal information, we invite you to read our General Privacy Notice for Business Partners.

Technical Support

Prescribing information can be found at the links below:

ADAKVEO®▼ (crizanlizumab) | EXJADE®▼ (deferasirox) | JAKAVI® (ruxolitinib) | KYMRIAH®▼ (tisagenlecleucel)

REVOLADE® (eltrombopag) | RYDAPT®▼(midostaurin) | TASIGNA® (nilotinib) / GLIVEC®▼ (imatinib)